On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

One group received standard care, while the other got standard care plus apixaban (2.5 mg twice daily ... and didn't require stopping the drug. The findings, published in Kidney International ...

Eliquis is taken to treat or prevent blood clots (such as ... Xarelto is available in four different strengths of tablets: 2.5 mg, 10 mg, 15 mg, and 20 mg. It also comes in pre-flavored oral ...

Since 2021, the hospital has offered a routine therapeutic drug monitoring (TDM) service for measuring rivaroxaban ... μL of the internal standard solution in an EP tube, vortexed for 5 min, and ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning ...

Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

or 10 mg (5 mg twice daily; the full-dose group) of apixaban for an additional 12 months. Neither patients nor their doctors knew which dose patients were receiving until the end of the trial.

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

or 10 mg (5 mg twice daily; the full-dose group) of apixaban for an additional 12 months. Neither patients nor their doctors knew which dose patients were receiving until the end of the trial.

Eliquis (apixaban) is a brand-name prescription drug that’s prescribed for certain dangerous blood clots. Specifically, Eliquis is approved for use in adults to: Eliquis has boxed warnings.